Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle cell pain in the emergency department
source: National Institute for Children’s Health Quality
Sickle cell disease is characterized by unpredictable episodes of extreme pain, known as acute vaso-occlusive episodes (VOE) or pain episodes, caused when sickled red blood cells are unable to move freely through blood vessels. In addition to pain, these changes at the cellular level can also lead to organ damage, stroke and even death. Pain episodes are the most common reason for emergency department (ED) visits and hospitalizations for patients with sickle cell disease. Detailed guidelines and quality indicators for the management of pain episodes currently exist, but both pediatric and adult patients with the disease often experience prolonged periods of waiting for treatment in the emergency department and ineffective treatment of their pain.
Delays in treatment are often due to systemic factors, such as the lack of a clear treatment protocol or limited provider experience in treating sickle cell diseaserelated pain. Prolonged waits for effective pain relief can lead to unnecessary suffering, hospitalizations, chronic pain syndromes, other complications and increased health care costs.1,8,10-12 Ensuring patients receive timely, effective pain relief is one of the most important elements of delivering high quality care to individuals with sickle cell disease in the emergency department.
Patient controlled analgesia for adults with sickle cell disease awaiting admission from the emergency departmentBackground: A treatment algorithm for s...
The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso-occlusive crisesSickle Cell Disease (SCD) is a painful, ...
Our Healthcare System Abandons Adult Sickle Cell PatientsWhen Janoi Burgess was a child, he thoug...
New Guidelines for Managing Sickle Cell Disease Presented at ACP Internal Medicine MeetingNew guidelines for therapeutic strategie...
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Cr...SANGUINATE™, the only investigational ...
A multiple drug approach to preventing sickle cell crisisSickle cell disease is characterized by ...
GBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.